

19 July 2024

Haematology and Immunoglobulin Treatments

I have a freedom of information request. Could you please answer the following questions:

Q1. In the past 3 months, how many patients have received the following treatments (for any disease):

- **Berinert (Human C1-esterase inhibitor)**
- **Cinryze (Human C1-esterase inhibitor)**
- **Firazyr (Icatibant)**
- **Icatibant - any brand except Firazyr**
- **Orladeyo (Berotralstat)**
- **Ruconest (Recombinant human C1-esterase inhibitor)**
- **Takhzyro (Lanadelumab)**

Q2. In the past 3 months, how many patients have received the following immunoglobulin treatments (for any disease):

- **Cutaquig**
- **Cuvitru**
- **Gammagard**
- **Gammanorm**
- **Hizentra**
- **Hyqvia**
- **Intratect**
- **Iqymune**
- **Kiovig**
- **Privigen**
- **Octagam**
- **Panzyga**
- **Subgam**
- **Any other normal immunoglobulin**

We are unable to provide a report that covers patient numbers our information system will only give activity per drug and not per numbers of patients. Some immunoglobulins are issued across other medical specialities as the request is not disease specific, again this would take time to interrogate.

This information is not centrally held. To undertake this exercise would necessitate a manual trawl of records and interrogation of data which would involve a significant number of hours. This would exceed the costs limit specified in the FOI act.

19 July 2024

We estimate that compliance with this (element of the) request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.